A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
Active, not recruiting · NCT02951598
Conditions: Alzheimer Disease, Mild Cognitive Impairment
At a glance
- Research payments reported, 2025
- $84,525
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,400
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Florbetapir F 18 PET Scan (drug)
- Dates
- Started 2016-10-29; completion 2026-04-28
- Results posted
- Not yet
The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered.
From ClinicalTrials.gov, last updated 2025-10-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $84,525 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Irvine Center for Clinical Research Inc $84,525
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.